WO1994014962A1 - Vaccines against varicella-zoster virus (vzv) - Google Patents

Vaccines against varicella-zoster virus (vzv) Download PDF

Info

Publication number
WO1994014962A1
WO1994014962A1 PCT/EP1993/003626 EP9303626W WO9414962A1 WO 1994014962 A1 WO1994014962 A1 WO 1994014962A1 EP 9303626 W EP9303626 W EP 9303626W WO 9414962 A1 WO9414962 A1 WO 9414962A1
Authority
WO
WIPO (PCT)
Prior art keywords
vzv
iep
protein
dna
derivative
Prior art date
Application number
PCT/EP1993/003626
Other languages
English (en)
French (fr)
Inventor
Paul Jacobs
Marc Massaer
Michèle HAUMONT
Alex Bollen
Original Assignee
Smithkline Beecham Biologicals (S.A.)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biologicals (S.A.) filed Critical Smithkline Beecham Biologicals (S.A.)
Priority to AU58144/94A priority Critical patent/AU672870B2/en
Priority to JP6514805A priority patent/JPH08504592A/ja
Priority to KR1019950702600A priority patent/KR950704494A/ko
Priority to EP94903844A priority patent/EP0675957A1/de
Publication of WO1994014962A1 publication Critical patent/WO1994014962A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present invention relates to the production of Varicella-Zoster virus (VZV) immediate early protein 175 and derivates thereof and vaccines for use in the prophylaxis and treatment of VZV infections, comprising such proteins.
  • VZV Varicella-Zoster virus
  • VZV Varicella-Zoster Virus
  • variants Humida-Zoster Virus
  • shingles zoster
  • VZV is a human herpes virus which is the etiological agent of chicken pox (varicella) and shingles (zoster).
  • Varicella results from an initial, or primary infection, usually contracted during childhood which is relatively benign. However, for adults who were not exposed to varicella during childhood, and occasionally to individuals who are immunocomprised, VZV can be life-threatening. Similarly, a VZV infection can be life-threatening to neonates, for the virus is capable of crossing the placenta. With direct contact, varicella is known to be a highly transmissible infectious disease.
  • VZV Varicella-Zoster
  • VZ Varicella-Zoster
  • This reactivation of the VZ virus causes an estimated 5 million cases of zoster annually (Plotkin £l a . Postgrad Med I £- 155-63 (1985)).
  • Zoster is characterized by inflammation of the cerebral ganglia and peripheral nerves, and it is associated with acute pain. At present, the factors that reactivate the virus are ill defined.
  • any virus coded polypeptide not just those that are integral membrane proteins like the glycoproteins can be a potential targets of T cell mediated responses.
  • VZV genome codes for several non structural proteins and internal virion proteins, in addition to external glycoproteins, this results in a large number of potential CTL targets and it is not known which protein would be the most relevant.
  • VZV infection is characterized by minimal presence of free virus. During latency and reactivation virus is mainly intracellular.
  • recurrent disease is not prevented even by high levels of neutralizing antibodies and virus control depends on cell mediated immunity.
  • An effective vaccine should prime CTL capable of acting as early as possible as soon as signs of reactivation of latent virus appear.
  • VZV replicative cycle In order to identify the most important CTL target antigens for prophylatic or therapeutic vaccine purposes, the present inventors have taken into consideration the VZV replicative cycle. The beginning of viral protein synthesis inside a cell that harbours viral genome will generate viral protein fragments that will be presented by MHC molecules on the surface of the cell, making it a target for CTL of the appropriate specificity.
  • the replication cycle of VZV lasts about 24 hours and involves an ordered expression of ⁇ or immediate early (IE) ⁇ or early (E) and ⁇ or late (L) gene products. Therefore early CTL attack and consequent lysis of the infected cells prior to late structural gene expression could prevent new virions being made and therefore prevent spread of the virus to neighbouring cells.
  • CTL should detect the very first viral proteins that appear inside the cell after infection and reactivation.
  • the IE protein IEP 175 is encoded by the open reading frame designated ORF62 and the protein itself is sometimes referred to as IE62.
  • the protein appears to be a phosphoprotein with a relative molecular weight 175kDa (Kinchinton ⁇ i J- of Virology Vol 66(1) (1992) p359-366), but a predicated molecular weight of 140kDa. It is recognised by Human T cells (Bergen et al Viral Immunology 4 (3) 1991 p 151) and has been suggested to be an important immune target (Bergen sLS ⁇ J. Infectious Diseases (1990) 1£2 p 1049).
  • IEP 175 and structually equivalent can be produced by expression in CHO cells.
  • IEP 175 free from VZV contaminants which is functionally equivalent to the native protein.
  • the present invention also extends to physiologically functional derivatives of IEP175.
  • an IEP 175 protein devoid of VZV contaminants having an amino acid sequence substantially homologous to the sequence depicted in figure 1 appended hereto.
  • substantially homologous it is meant a the invention provides a functionally equivalent IE 175 protein which is at least 75% homologous, preferably 80% more preferably at least 90% and most preferably at least 95% homologous to the amino acid sequence depicted in figure 1.
  • a preferred derivative of IEP 175 is one which will allow for secretion of the protein on expression in E. Coli or CHO cells.
  • a secretable derivative in which amino acids 226 to 257 and amino acids 648 to 733 have been deleted.
  • Typical of other immunogenic derivatives will be a fusion polypeptide containing additional sequences which can carry one or more epitopes from other VZV proteins such as VZV glycoproteins eg gpl, gpll, gpIII, gpIV or gpV, (sometimes known as gel, gcll, gcM etc) other VZV antigens, or even other non- VZV antigens eg Hepatitis B surface or core antigens.
  • the immunogenic derivative of the invention can be fused t ⁇ a carrier polypeptide which has immunostimulating properties, as in the case of an adjuvant, or which otherwise enhances the immune response to the VZV protein, or which is useful in expressing, purifying or formulating the VZV protein.
  • a preferred fusion protein comprises an anchorless gpll fused to a secretable form of IEP 175 as described above.
  • the present invention provides an expressible DNA molecule encoding IEP 175 or derivatives thereof under the control of a regulatory sequence, which is capable of functioning in a heterologous host.
  • substantially homologous it is meant a DNA sequence which is at least 75% preferably at least 85% more preferably 90% and most preferably at least 95% homologous to the DNA sequence depicted in figure 1.
  • DNA sequences encoding IEP 175 or derivatives can be prepared by the addition, deletion, substitution or rearrangement of the bases, by methods well known in the art.
  • the first ATG codes for a N-te ⁇ ninal methionine and the last TGA is a translation termination (ie stop) signal.
  • a recombinant DNA molecule or vector comprising a DNA sequence, which codes for Varicella-Zoster Virus IEP 175 or derivate thereof, operatively linked to a regulatory region which functions in a eukaryotic host cell, most preferably in a CHO cell.
  • this invention provides a recombinant CHO cell line transformed with the recombinant DNA molecule.
  • the invention provides a process for preparing a VZV IE 175 protein or derivative according to the invention which process comprises expressing a DNA sequence encoding said protein or derivative in a recombinant host cell and recovering the resulting protein product.
  • the process of the invention may be performed by conventional recombinant techniques such as described in Maniatis £i si, Molecular Cloning - A Laboratory Manual; Cold Spring Harbor, 1982 and DNA Cloning vols I, II and III (D.M. Glover ed, IRL Press Ltd).
  • DNA molecules comprising such coding sequences can be derived from VZV mRNA using known techniques (eg making complementary or cDNAs from a mRNA template) or can be isolated from VZV genomic DNA. See Ecker et al, Proc Natl cad Sci USA 22:156-160 (1982), Straus et al, Pr ⁇ x? Natf A ⁇ ad Sci USA 22:993-7 (1982), Straus et al. J Gen Virol 64:1031-41 (1983) and Davison et al. J Gen Virol £4:1811-1814 (1983). Alternatively the DNA molecules encoding gpl, gpll and gpIII can be synthesized by standard DNA synthesis techniques.
  • the invention thus also provides a process for preparing the DNA sequence by the condensation of appropriate mono-, di- or oligomeric nucleotide units.
  • the preparation may be carried out chemically, enzymatically, or by a combination of the two methods, in vitro or in vivo as appropriate.
  • the DNA sequence may be prepared by the enzymatic ligation of appropriate DNA fragments, by conventional methods such as those described by D M Roberts £1 al in Biochemistry 1985, 24, 5090-5098.
  • the DNA fragments may be obtained by digestion of DNA containing the required sequences of nucleotides with appropriate restriction enzymes, by chemical synthesis, by enzymatic polymerisation, or by a combination of these methods.
  • Digestion with restriction enzymes may be performed in an appropriate buffer at a temperature of 20°-70°C, generally in a volume of 50 ⁇ g or less with 0.1- lO ⁇ g DNA.
  • Enzymatic polymerisation of DNA may be carried out in vitro using a DNA polymerase such as DNA polymerase I (Klenow fragment) in an appropriate buffer containing the nucleotide triphosphates dATP, dCTP, dGTP and dTTP as required at a temperature of 10°-37°C, generally in a volume of 50 ⁇ l or less.
  • a DNA polymerase such as DNA polymerase I (Klenow fragment) in an appropriate buffer containing the nucleotide triphosphates dATP, dCTP, dGTP and dTTP as required at a temperature of 10°-37°C, generally in a volume of 50 ⁇ l or less.
  • Enzymatic ligation of DNA fragments may be carried out using a DNA ligase such as T4 DNA ligase in an appropriate buffer at a temperature of 4°C to ambient, generally in a volume of 50 ⁇ l or less.
  • the chemical synthesis of the DNA sequence or fragments may be carried out by conventional phosphotriester, phosphite or phosphoramidite chemistry, using solid phase techniques such as those described in 'Chemical and Enzymatic Synthesis of Gene Fragments - A Laboratory Manual' (ed H.G. Gassen and A. Lang), Verlag Chemie, Weinheim (1982), or in other scientific publications, for example M.J. Gait, H.W.D. Matthes, M. Singh, B.S.
  • the DNA sequence is preferably prepared by ligating two or more DNA molecules which together comprise a DNA sequence encoding the protein.
  • the DNA molecules may be obtained by the digestion with suitable restriction enzymes of vectors carrying the required coding sequences.
  • DNA molecules and the way in which they are obtained depends upon the structure of the desired protein product.
  • design of a suitable strategy for the construction of the DNA molecule coding for the protein is a routine matter for the skilled worker in the art.
  • the expression vector may be prepared in accordance with the invention, by cleaving a vector compatible with the host cell to provide a linear DNA segment and combining said linear segment with one or more DNA molecules which, together with said linear segment, encode the IE175 protein, or derivative under ligating conditions.
  • the ligation of the linear segment and more than one DNA molecule may be carried out simultaneously or sequentially as desired.
  • the DNA sequence may be preformed or formed during the construction of the vector, as desired.
  • the choice of vector will be determined in part by the host.
  • the preferred host cell of the invention is a CHO cell.
  • Suitable vectors for the host cell of the invention include plasmids, and cosmids.
  • the preparation of the IE 175 expression vector may be carried out conventionally with appropriate enzymes for restriction, polymerisation and ligation of the DNA, by procedures described in, for example, Maniatis ej L cited above. Polymerisation and ligation may be performed as described above for the preparation of the DNA polymer. Digestion with restriction enzymes may be performed in an appropriate buffer at a temperature of 20°-70°C, generally in a volume of 50 ⁇ l or less with 0.1-10 ⁇ g DNA.
  • the recombinant host cell is prepared, in accordance with the invention, by transforming a host cell with an expression vector of the invention under transforming conditions. Suitable transforming conditions are conventiional and are described in, for example, Maniatis ei al, cited above, or "DNA Cloning" Vol. II, D.M. Glover ed., IRL Press Ltd, 1985.
  • Mammalian cells in culture may be transformed by calcium co-precipitation of the vector DNA onto the cells or by electroporation.
  • Culturing the transformed host cell under conditions permitting expression of the DNA sequence is carried out conventionally, as described in, for example, Maniatis £i ai and "DNA Cloning" cited above.
  • the cell is supplied with nutrient and cultured at a temperature below 45°C.
  • the VZV IE 175 protein expression product is recovered by conventional methods according to the host cell and whether the product is secreted or released chemically or enzymatically and the protein product isolated from the resulting lysate. Where the product is secretable, the product may generally be isolated from the nutrient medium.
  • the DNA sequence may be assembled into vectors designed for isolation of stable transformed mammalian cell lines expressing the IEP 175 protein; eg bovine papillomavirus vectors or amplified vectors in Chinese hamster ovary cells (DNA cloning Vol.II D.M. ed. IRL Press 1985; Kaufman, R.J. ej al, Molecular and Cellular Biology 5, 1750-1759, 1985; Pavlakis G.N. and Hamer, D.H., Proceedings of the National Academy of Sciences (USA) 80, 397-401, 1983; Goddel, D.V. et al. European Patent Application No. 0093619, 1983).
  • IEP 175 protein eg bovine papillomavirus vectors or amplified vectors in Chinese hamster ovary cells (DNA cloning Vol.II D.M. ed. IRL Press 1985; Kaufman, R.J. ej al, Molecular and Cellular Biology 5, 1750-1759, 1985
  • the VZV IEP 175 protein is expressed in CHO cells.
  • the use of the Tdn expression plasmid is preferred.
  • an expression cassette, comprising the VZV protein coding sequence is operatively linked to the Rous Sarcoma Virus (RSV) promoter.
  • RSV Rous Sarcoma Virus
  • Such vector contains a sufficient amount of bacterial DNA to propagate in E. coli or some other suitable prokaryotic host.
  • Such shuttle vector also contains sufficient amount of eukaryotic DNA flanking the VZV coding sequence so as to permit recombination into the genome of the eukaryotic host and amplification of the integrated DNA using Methotrexate as selective agent.
  • the promoter of the RSV is preferred because of its high efficiency in promotion of transcription as compared to other promoters.
  • VZV IEP 175 protein or derivative from cell culture is carried out by conventional protein isolation techniques, eg selective precipitation, abso ⁇ tion chromatography, and affinity chromatography including a monoclonal antibody affinity column.
  • This invention also relates to a vaccine containing an immunoprotective amount of VZV IEP 175 protein(s) according to the invention.
  • immunoprotective refers to a sufficient amount of VZV IEP175 protein(s), when administered to man, which elicits a protective antibody or immune response against a subsequent VZV infection sufficient to avert or mitigate the disease.
  • the present invention provides a vaccine formulation comprising VZV IEP 175 or derivative thereof in admixture with a pharmaceutical carrier, excipient or diluent.
  • the vaccine of the present invention may additionally contain other antigenic components such as VZV gpl, gpll, gpIII, gpIV or gpV or their truncated derivatives.
  • VZV gpl, gpll, gpIII, gpIV or gpV or their truncated derivatives.
  • truncated gpl, gpll or gpIII as disclosed in European Patent application published under No. 0405867.
  • a vaccine composition comprising an anchorless gpll in combination with IEP 175 or IEP 175 derivative.
  • anchorless it is meant, a VZV glycoprotein derivative which is devoid of substantially all of the C-terminal anchor region and which allows for secretion on when expressed in mammalian cells.
  • Such proteins are described in EP-A-0405867.
  • a vaccine comprising a fusion protein comprising an amino acid sequence embodying IEP 175 or derivative and amino acid sequence embodying one of gpl, gpll, gpIII, gpIV or gpV or derivative thereof.
  • VZV IEP 175 or derivative thereof for the manufacture of a vaccine for the treatment or prophylaxis of VZV infections.
  • the present invention also provides VZV IEP 175 or derivative thereof for use in medicine.
  • a method of treating a human susceptible to or suffering from VZV infection which comprises administering a safe and effective amount of a vaccine according to the invention.
  • each vaccine dose is selected as an amount which induces an immunoprotective response without significant, adverse side effects in typical vaccinees. Such amount will vary depending upon which specific immunogen is employed and how it is presented. Generally, it is expected that each dose will comprise 1-1000 ⁇ g of protein, preferably 2-100 ⁇ g, most preferably 4-40 ⁇ g. An optimal amount for a particular vaccine can be ascertained by standard studies involving observation of appropriate immune responses in subjects. Following an initial vaccination, subjects may receive one or several booster immunisation adequately spaced.
  • compositions of the present invention may be used to treat, immunotherapeutically, patients suffering from VZV infections, in order to prevent or significantly decrease recurrent disease, frequency, severity or duration of shingles episodes.
  • an aqueous solution of the VZV IEP 175 protein(s) can be used directly.
  • the VZV IEP 175 protein(s), with or without prior lyophilization can be mixed together or with any of the various known adjuvants.
  • adjuvants include, but are not limited to, aluminium hydroxide, muramyl dipeptide and saponins such as Quil A, in particular QS21 or 3 Deacylated monophosphoryl lipid A (3D-MPL).
  • the protein can be encapsulated within microparticles such as liposomes.
  • the VZV IEP175 protein(s) can be conjugated to an immunostimulating macromolecule, such as killed Bordetella or a tetanus toxoid.
  • Vaccine preparation is generally described in New Trends and Developments in Vaccines, Voller et al. (eds), University Park Press, Baltimore, Maryland, 1978. Encapsulation within liposomes is described by Fullerton, US Patent 4,235,877. Conjugation of proteins to macromolecules is disclosed, for example, by Likhite, US Patent 4,372,954 and Armor et al., US Patent 4,474,757. Use of Quil A is disclosed by Dalsgaard et al., Acta Vet Scand. 18:349 (1977). 3D-MPL is available from Ribi immunochem, USA, and is disclosed in British Patent Application No. 2,220211 and US Patent 4912094. QS21 is disclosed in US patent No. 5057540.
  • IEP 175 Expression of IEP 175 in cells infected with a vaccinia virus recombinant.
  • VZV geomic DNA was extracted from viruses recovered from a patient suffering from Varicella (Material provided by Dr. Rentier, Institut de Pathologie, Universit ⁇ de vide, Sart-Tilman,Liege, Belgium).
  • the viral DNA was digested with EcoRl and a ⁇ 16.6 kb-pair fragment, corresponding to bases 100441 to 117034 (Davison et al, J. Gen Virology 67, 1759- 1816, 1986) was isolated then cloned into the EcoiRl site of plasmit pUC9, a standard E. coli cloning vector. From this plasmid, a ⁇ 7 Kb Sspl fragment (102241 to 109293) was isolated and cloned into the incil site of pUC19 to create plasmid pNIV2017. This plasmid encodes the entire IEP 175 protein plus 5' and 3' untranslated DNA.
  • Plasmid pNIV2017 was then digested with a set of restriction enzymes to generate three fragments : a BstXI-BamHI fragment of 2199 bp coding for the N- terminal part of the protein; a BamHI-PpumI fragment of 1002 bp and a Ppuml- Maelll 728 bp fragment coding for the C-terminal part of the protein.
  • Synthetic oligonucleotides were added to these fragments to generate a coding cassette flanked by unique restriction sites.
  • the coding cassette was introduced into pUC19 for preservation (plasmid pNIV2020). The sequence of the oligonucleotides and their junction were confirmed.
  • the IEP 175 coding cassette was recovered from pNIV2020 and then inserted into the transfer vector pULB5213, a derivative of plasmid pSCl 1 described in Chakrabarti et al (Molecular and Cellular Biology 5, 3403-3409, 1985).
  • the final construct, ⁇ NIV2026, is represented in Figure 2.
  • the recombinant transfer plasmid, pNIV2026 was transfected into vaccinia- infected CV-1 cells and recombinant viruses were isolated after Bromo-Uridine slection and plaque purification on the basis of their blue colour in the presence of X- gal. It will be referred to as VV2026.
  • the human H143 fibroblast TK- strain was used preferably to the RAT2 cells for plaque assays.
  • the vaccinia virus used to infect cells was of the WR type (origin Borysiewicz L.K.). The procedure follows that one previously described for the obtention of vaccinia virus recombinants (Mackett, M. and Smith, G.L., J. Gen. Virology 67, 2067-2082, 1986; Mackett, M., Smith, G.L. and Moss, B., J. Virology 49, 857-864, 1984).
  • the recombinant vaccinia virus, VV2026 was used to infect CV-1 cells in culture at a multiplicity of infection of 1 (moi 1). Infected cells (about 3 10*5 per assay) and spent culture medium (about 2 ml) were collected between 16 and 17 hours post infection.
  • the presence of the IEP 175 protein was identified by Western blotting experiments. Proteins were resolved onto 12% SDS-polyacrylamide gels, transferred onto nitrocellulose filters and probed with a mouse serus raised against a synthetic peptide derived from the amino acid sequence of the IEP 175 protein (aa 1299 to 1310). Complexes were detected using a goat anti-mouse IgG conjugated to alkaline phosphatase and the appropriate chromogenic substrate, according to standard procedures.
  • the results show that cells infected with VV2026 effectively accumulate the IEP 175 protein in the cytoplasm but are not able to export it in the medium.
  • the size of the recombinant protein was about 150 K
  • IEP 175 Expression of IEP 175 in cells insect cells infected with a recombinant Baculovirus.
  • the cassette coding for IEP 175 was recovered by digestion with EcoRI and Xbal and inserted blunt-ended into the Baculovirus transfer plasmid pAcYMl, previously cut with BamHI and blunted.
  • the resulting recombinant plasmid pNIV2038 thus carries, under the control of the polyhedrin promoter and in the correct orientation, the sequence coding for IEP 175 (Fig.3.)
  • Plasmid pAcYMl is a Baculovirus shuttle vector containing sequences from the AcMNPV genome which includes the polyhedrin gene promoter, but not the polyhedrin gene, and sequences from a high copy bacterial plasmid, pUC8. See Matauura et al, J. Gen. Virol. 68, 1233-1250 (1987).
  • the recombinant baculovirus transfer plasmid pNTV2038 was introduced by contransfection with the wild type DNA Baculovirus into Spodoptera frugiperda (Sf9) insect cells at a respective ratio of 50 to 1 ⁇ g, following published protocols (Summers et al, TAES Bulletin NR 1555, May 1987; Texas Agricultural Experimental Station). Spodoptera frugiperda cells (Sf9) are available from the ATCC (Rockville, Md, USA).
  • Resulting virus particles were obtained by collecting the supernatants. The virus-containing media was then used to infect Sf9 cells in a plaque assay. Several recombinant Baculoviruses were isolated and purified. They were then used to infect Sf9 cells in Culture. Total proteins of infected cells were recovered at different times post-infection and assayed by Western blotting for the presence of IEP 175, using the mouse antipeptide serum specific for IEP 175 (see supra). In no cases, were we able to demonstrate the expression of a complete IEP 175 in this sytem. We observed however the expression of multiple truncated forms of the protein, indicating that extensive proteolytic degradation occurred intracellularly.
  • the recombinant baculovirus transfer plasmid pNIV2038 is depicted in figure 3.
  • Plasmid TDN is described in Connors et al, DNA 7, 651 - 661 (1988). It carries the RSV LTR promoter, the G418 selection marker and the DHFR cassette of amplification.
  • pNVI2042 codes for the signal peptide of the tissue plasminogen activator (tPA) followed by 4 amino acid residues corresponding to the N-terminal amino acid residues of mature tPA, themselves followed by the naturally initiating methionine of EEP 175 and the complete sequence of this protein (Fig.l). Plasmid pNIV2042 was introduced by electroporation into CHO dhfr " cells. Selection of recombinant cell lines was done using geneticin (G418) and amplification was performed using methotrexate. All procedures used follow those described in Moguilevsky et al. (Eur. J. Biochem 197, 605-614, 1991). G418- clones were obtained and assayed for the production of the full size
  • IEP 175 protein using the system described supra. Clones shown to produce the recombinant protein were amplified with methotrexate at different concentrations (from 5 to 50 nM) and retested for production. The results show that IEP 175 is produced efficiently in CHO cells, that it accumulates in the cytoplasm and that its apparent molecular weight is around 175 kDalton. No proteolytic degradation was observed in the CHO expression system in contrast to what was observed in the insect cell sytem. The best producing clone, 18.5.22, was obtained after amplification with 50 nM methotrexate.
  • IEP 175 The production of IEP 175 was monitored using an ELISA involving two mouse antipeptide sera specific for the protein (peptide 1299 to 1310 and peptide 175-436). Western blot analysis, performed as described above, confirmed the structural integrity of the recombinant IEP 175. Unexpectedly, the recombinant IEP 175 was not secreted into the culture medium of CHO cells despite the presence of a signal peptide sequence on the DNA for IEP 175.
  • the expression plasmid pNIV2042 for CHO cells is depicted in figure 4.
  • the recombinant IEP protein is not only structurally appropriate but also that it exhibits the known regulatory function of the natural protein, we performed the following experiments (references : Jackers et al, 1992; Liny et al, 1992).
  • CHO. cells expressing the IEP 175 protein, clone 18-5-22, and control CHO cells were electroporated with a set of plasmids carrying various VZV promotor DNA sequences upstream to the coding sequence for the reporter gene chloramphenicol acyl transferase (CAT).
  • CAT chloramphenicol acyl transferase
  • Table 1 summarizes the results of these experiments. It can be seen that the IEP 175 protein, produced in CHO cells, is able to stimulate the promotor activity in several cases. This shows that the recombinant IEP 175 protein behaves in this respect as its natural counterpart.
  • Table 1 Functional activation of VZV promotor elements by rec IEP 175 (as measured by CAT activity).
  • VZV promotor element CHO cell line derived from gene Control Clone 18-5-22 Conclusion
  • Plasmid pNIV2020 (see example 1) carries the sequence coding for the complete IEP 175 protein, including the two karyophilic motifs. These have the following amino acid sequences. Motif 1 is comprised between aa residues 226 and 254 and contains the nucleophilic amino acid stretch KSPKKKTLKVK; motif 2 is comprised between aa residues 648 and 733 and contains the nucleophilic amino acid stretch PRKRKS. Digestion of pNIV2020 with a) Aatll and SphI; b) PpumI and BstEII; appropriate blunting, are ligated together to reconstitute a plasmid lacking the DNA sequences containing the karyophilic motifs ( Figure 5). 4b. The cassette encoding the resulting truncated IEP 175 is recovered and is inserted into a plasmid downstream to the sequence specifying the tPA signal in the manner described in Example 3.
  • Transformation of CHO cell with the resulting plasmid will allow for expression of IEP 175 in a secreted form.
  • the fragment described in 4b is inserted in a plasmid as a fusion downstream to the sequence encoding gcll (EP-A-405 867).
  • the resulting plasmid is used to transform CHO cells to enable expression of an IEP 175 truncate gcll truncate fusion protein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PCT/EP1993/003626 1992-12-23 1993-12-17 Vaccines against varicella-zoster virus (vzv) WO1994014962A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU58144/94A AU672870B2 (en) 1992-12-23 1993-12-17 Vaccines against varicella-zoster virus (VZV)
JP6514805A JPH08504592A (ja) 1992-12-23 1993-12-17 水痘−帯状疱疹ウイルス（ｖｚｖ）に対するワクチン
KR1019950702600A KR950704494A (ko) 1992-12-23 1993-12-17 수두-대상포진 바이러스(vzv)에 대한 백신(vaccines against varicellazoster virus(vzv))
EP94903844A EP0675957A1 (de) 1992-12-23 1993-12-17 Impfstoff gegen varicella-zoster virus(vzv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929226768A GB9226768D0 (en) 1992-12-23 1992-12-23 Vaccines
GB9226768.1 1992-12-23

Publications (1)

Publication Number Publication Date
WO1994014962A1 true WO1994014962A1 (en) 1994-07-07

Family

ID=10727070

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1993/003626 WO1994014962A1 (en) 1992-12-23 1993-12-17 Vaccines against varicella-zoster virus (vzv)

Country Status (11)

Country Link
EP (1) EP0675957A1 (de)
JP (1) JPH08504592A (de)
KR (1) KR950704494A (de)
CN (1) CN1095106A (de)
AU (1) AU672870B2 (de)
CA (1) CA2152256A1 (de)
GB (1) GB9226768D0 (de)
MX (1) MX9307998A (de)
NZ (1) NZ259362A (de)
WO (1) WO1994014962A1 (de)
ZA (1) ZA939564B (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043527A1 (en) * 1999-01-20 2000-07-27 Smithkline Beecham Biologicals S.A. Varicella-zoster virus vaccines
CN110343722A (zh) * 2019-07-03 2019-10-18 上海大学 一种重组表达水痘-带状疱疹病毒v-Oka株截短型糖蛋白E的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0405867A1 (de) * 1989-06-27 1991-01-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Verbindungen
EP0510996A1 (de) * 1991-04-26 1992-10-28 The Research Foundation For Microbial Diseases Of Osaka University Rekombinanter Varicella-Zoster-Virus-Vektor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0405867A1 (de) * 1989-06-27 1991-01-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Verbindungen
EP0510996A1 (de) * 1991-04-26 1992-10-28 The Research Foundation For Microbial Diseases Of Osaka University Rekombinanter Varicella-Zoster-Virus-Vektor

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ARVIN ET AL.: "Equivalent recognition of a Varicella-Zoster Virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype", JOURNAL OF IMMUNOLOGY, vol. 146, no. 1, 1 January 1991 (1991-01-01), pages 257 - 264 *
BERGEN ET AL.: "Human T cells recognize multiple epitopes of an immediate early/tegument protein (IE62) and glycoprotein I of Varicella Zoster Virus", VIRAL IMMUNOLOGY, vol. 4, no. 3, 1991, pages 151 - 166 *
DAVISON ET AL.: "DNA sequence of the major inverted repeat in the Varicella-Zoster Virus genome", JOURNAL OF GENERAL VIROLOGY, vol. 66, no. PT2, February 1985 (1985-02-01), pages 207 - 220 *
FELSER ET AL.: "Cell lines containing Varicella-Zoster Virus open reading frame 62 and expressing the "IE"175 protein complement ICP4 mutants of Herpes Simplex Virus type 1", JOURNAL OF VIROLOGY, vol. 62, no. 6, June 1988 (1988-06-01), pages 2076 - 2082 *
KINCHINGTON ET AL.: "The varicella-Zoster Virus immediate early protein IE62 is a major component of virus particles", JOURNAL OF VIROLOGY, vol. 66, no. 1, January 1992 (1992-01-01), pages 359 - 366 *
LOWRY ET AL.: "Immunity in strain 2 guinea-pigs inoculated with vaccinia virus recombinants expressing Varicella-Zoster Virus glycoproteins I, IV, V or the protein product of the immediate early gene 62", JOURNAL OF GENERAL VIROLOGY, vol. 73, no. PT4, April 1992 (1992-04-01), pages 811 - 819 *
SHARP ET AL.: "Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine", JOURNAL OF INFECTIOUS DIDEASES, vol. 165, no. 5, May 1992 (1992-05-01), pages 852 - 858 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043527A1 (en) * 1999-01-20 2000-07-27 Smithkline Beecham Biologicals S.A. Varicella-zoster virus vaccines
CN110343722A (zh) * 2019-07-03 2019-10-18 上海大学 一种重组表达水痘-带状疱疹病毒v-Oka株截短型糖蛋白E的方法

Also Published As

Publication number Publication date
CN1095106A (zh) 1994-11-16
AU5814494A (en) 1994-07-19
ZA939564B (en) 1994-08-15
JPH08504592A (ja) 1996-05-21
CA2152256A1 (en) 1994-07-07
EP0675957A1 (de) 1995-10-11
KR950704494A (ko) 1995-11-20
NZ259362A (en) 1996-10-28
AU672870B2 (en) 1996-10-17
MX9307998A (es) 1994-08-31
GB9226768D0 (en) 1993-02-17

Similar Documents

Publication Publication Date Title
EP0405867B1 (de) Verbindungen
EP0139417B1 (de) Vakzine auf Basis membrangebundener Proteine und Verfahren zu ihrer Herstellung
JP3826055B2 (ja) 組換えアビポックスウイルスによる免疫方法
DK172635B1 (da) Polypeptid og dets anvendelse i vaccine samt ekspressionssystem til dets eksprimering
JPH03501723A (ja) ヒト呼吸系シンシチウムウイルスの糖蛋白類の免疫原性セグメントを含有するキメラ糖蛋白類
US6020309A (en) Pharmaceuticals based on papillomaviruses
EP0433371A1 (de) Fusionsprotein von paramyxovirus, verfahren zur herstellung unter verwendung von rekombinant-baculovirus-expressionsvektor, impfstoff, die dieses enthalten, und verwendung
US5795579A (en) Herpes simplex virus VP16 vaccines
EP0538341B1 (de) Ehv-4 glykoprotein vazin
WO1995016779A9 (en) Herpes-symplex-virus type 2 icp4 protein and its use in a vaccine composition
EP1529845B1 (de) Nicht spaltbare HCMV gB Proteine
WO2000043527A1 (en) Varicella-zoster virus vaccines
Ray et al. Expression of the fusion glycoprotein of human parainfluenza type 3 virus in insect cells by a recombinant baculovirus and analysis of its immunogenic property
AU672870B2 (en) Vaccines against varicella-zoster virus (VZV)
AU676166B2 (en) Immediate early HSV-2 viral protein ICP27 as vaccine
US5674735A (en) DNA encoding the EHV-4 gH or gC glycoprotein
AU719837B2 (en) Pharmaceuticals based on papillomaviruses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1994903844

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 259362

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2152256

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 1995 464801

Country of ref document: US

Date of ref document: 19950728

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1994903844

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1994903844

Country of ref document: EP